MADRID, 10 Nov. (EUROPA PRESS) –
The Danish pharmaceutical company Novo Nordisk, the second largest European company by market capitalization, only behind the French company LVMH, announced this Friday that it will allocate “more than 42,000 million crowns (5,631 million euros)” in the coming years to expand its manufacturing facilities in Denmark given the strong demand for its anti-obesity treatments, such as Wegovy, and anti-diabetes, such as Ozempic.
The announced investment will focus on expanding the manufacturing capabilities of its plant in Kalundborg, Denmark, creating additional capacity across the global value chain, from active pharmaceutical ingredient (API) manufacturing to packaging, to increase capacity. from Novo Nordisk to meet future market demand.
The construction projects are expected to be completed gradually between the end of 2025 and until 2029 and the company anticipates that they will allow the creation of 800 new jobs at the facilities once the construction and equipment of the facilities is completed, although during the phase of Construction will employ up to 3,000 external employees.
In the last two years, Novo Nordisk has announced production investments in Denmark worth 40 billion Danish crowns (more than 5.3 billion euros) and has added approximately 1,100 production employees related to these investments.
Likewise, earlier this year, Novo Nordisk confirmed that it was awaiting approvals for a new production site in Funen, Denmark.
